Not Yet RecruitingNot Applicable

Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

30 participantsStarted 2026-05-01

Plain-language summary

Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
. Splenomegaly and hypersplenism
. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
. Age 18-80 years, male or female
. Child-Pugh Class A or B liver function
. No history of primary renal disease or acute kidney injury (AKI)
. Signed written informed consent
. Ability to complete 24-month follow-up

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serum creatinine (Scr) level

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Glomerular filtration rate (eGFR)

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

BUN and UA level

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Urine albumin-to-creatinine ratio (UACR)

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Trial details

NCT IDNCT07585786

SponsorNorthern Jiangsu People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-02-28

Contact for this trial

Guo-Qing Jiang, MD

+8651487373272 jgqing2003@hotmail.com

View on ClinicalTrials.gov More Cirrhosis, Liver trials

Plain-language summary

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
. Splenomegaly and hypersplenism
. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
. Age 18-80 years, male or female
. Child-Pugh Class A or B liver function
. No history of primary renal disease or acute kidney injury (AKI)
. Signed written informed consent
. Ability to complete 24-month follow-up

What they're measuring

Serum creatinine (Scr) level

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Glomerular filtration rate (eGFR)

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

BUN and UA level

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Urine albumin-to-creatinine ratio (UACR)

Timeframe: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

Exclusion criteria